Small Cell Lung Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline NSCLC therapies in ...

引言如何在早期阶段精准诊断并评估癌症患者的预后风险，一直是一项具有重大挑战的课题。循环肿瘤DNA (circulating tumor DNA, ctDNA) ...

NeXT Personal, a liquid biopsy test offers early lung cancer detection through ctDNA analysis, improving survival predictions ...

Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...

本次研究由中国中医科学院广安门医院牵头，上海市中医医院肿瘤临床医学中心作为分中心，计划从2024年5月持续至2027年10月。研究过程中将持续收集与分析来自不同患者的临床数据，以确保结果的广泛性和应用价值。该研究已通过伦理审查，保证了所有参与者的权益。

[1] Datopotamab deruxtecan granted Priority Review in the US for patients with previously treated advanced EGFR-mutated ...

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Innovent Biologics Inc. (IVBXF.OB) and Jiangsu Aosaikang Pharmaceutical Co. Ltd. or ASK Pharm announced that China's National Medical ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab ...